SIGMAR1 and Cognitive impairment: Studies on in vivo mice have shown that fluvoxamine improved phencyclidine (PCP)-treated cognitive deficits in mice via Sig-1R activation, whereas sertraline and paroxetine did not improve PCP-treated cognitive deficits in the model; these investigations suggest that potential agonism for fluvoxamine and antagonism for sertraline at Sig-1R (Hashimoto et al., 2007).